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Summary
Eukaryotic cell division is often regulated by extracellular
signals. In budding yeast, signaling from mating phero-
mones arrests the cell cycle in G1 phase [1]. This arrest
requires the protein Far1 [2], which is thought to antagonize
the G1/S transition by acting as a Cdk inhibitor (CKI) [3, 4],
although the mechanisms remain unresolved [5]. Recent
studies found that G1/S cyclins (Cln1 and Cln2) recognize
Cdk substrates via specific docking motifs, which promote
substrate phosphorylation in vivo [6, 7]. Here, we show
that these docking interactions are inhibited by pheromone
signaling and that this inhibition requires Far1. Moreover,
Far1 mutants that cannot inhibit docking are defective at
cell-cycle arrest. Consistent with this arrest function, Far1
outcompetes substrates for association with G1/S cyclins
in vivo, and it is present in large excess over G1/S cyclins
during the precommitment period where pheromone
can impose G1 arrest. Finally, a comparison of substrates
that do and do not require docking suggests that Far1
acts as a multimode inhibitor that antagonizes both kinase
activity and substrate recognition by Cln1/2-Cdk complexes.
Our findings uncover a novel mechanism of Cdk regulation
by external signals and shed new light on Far1 function to
provide a revised view of cell-cycle arrest in this model
system.Results
During cell-cycle arrest by pheromones, Far1 is thought to act
as a Cdk inhibitor (CKI) that antagonizes cyclin-Cdk com-
plexes containing early cyclins (Cln1, Cln2, Cln3), which func-
tion in G1 to drive cell-cycle entry (Figure 1A). Far1 binds these
Cdk complexes in vivo [8] and appeared to inhibit Cln2-Cdk
activity in vitro [4], but later studies failed to detect this inhib-
itory effect [5], and others suggested that Far1 might inhibit
Cln3-Cdk or regulate Cln2 protein levels [9, 10]. Consequently,
the precise effects of pheromone and Far1 on Cdk function
in vivo have remained unresolved. Recent studies revealed
that some Cln-Cdk phosphorylation events require docking
interactions between Cln1/Cln2 and specific motifs in sub-
strate proteins, including components of the mating pathway
(Ste5 and Ste20) and regulators of the G1/S transition (Sic1
and Whi5) [6, 7]. Therefore, we asked whether pheromone
signaling and/or Far1 might disrupt these docking interac-
tions, either in addition to or as an alternative to direct inhibi-
tion of Cdk activity per se (Figure 1B).2Co-first author
*Correspondence: peter.pryciak@umassmed.eduTomonitor docking, we used an assay inwhich a glutathione
S-transferase (GST)-substrate fusion and an epitope-tagged
cyclin (Cln2) were coexpressed and coprecipitated [6]. (Here,
we took steps to prevent CLN2 expression and pheromone
signaling from interfering with each other; see the Supple-
mental Experimental Procedures and Figure S1 available
online.) First, we tested a GST fusion to a Cln2-binding frag-
ment of Ste20 (residues 72–333, designated Ste20*) [6],
expressed from an inducible promoter (PGAL1). Without phero-
mone, we observed Cln2-myc binding as soon as GST-Ste20*
expression was detected, but binding was strongly inhibited
when pheromone was included (Figure 1C). (Note that total
Cln2 levelswere often reduced by prolonged pheromone treat-
ments, as in earlier studies [10], so we used short treatment
times where possible to minimize this effect.) Pheromone
also inhibited Cln2-myc binding to another, similar GST fusion
(GST-Ste5*), in which the Cln2 docking site from Ste20 was
replacedwith one from Ste5 (Figure 1D). Remarkably, this inhi-
bition was not observed in far1D cells (Figure 1D). Therefore,
pheromone signaling can disrupt Cln2-substrate binding inter-
actions in a manner that depends on Far1.
Next, we tested the role of regulatory phosphorylation sites
in Far1 (Figure 2A): phosphorylation at residue T306 by the
MAPK Fus3 promotes Far1 function, whereas phosphoryla-
tion at residue S87 by Cdk triggers its degradation [5]. We
introduced nonphosphorylatable Ala mutations at these sites,
tested previously in an N-terminal fragment of Far1 [5], into
full-length Far1 expressed from the native FAR1 locus. As
expected, the T306A mutant was defective at pheromone
arrest, whereas the S87A mutant remained functional (Fig-
ure 2B); the S87A T306A double mutant showed an intermedi-
ate phenotype, indicating that T306 phosphorylation is not
absolutely required whether Far1 is stabilized by the S87A
mutation. When we tested Cln2-substrate binding in these
strains, we observed several notable features (Figures 2C
and 2D). First, the T306A mutation blocked the ability of pher-
omone to disrupt Cln2-substrate interactions, whereas the
S87A mutation increased this disruptive effect. Second, this
increased potency of the Far1-S87A mutant was evident
even in the absence of pheromone. Third, the S87A mutation
partially suppressed the defect of the T306Amutation, consis-
tent with the arrest phenotypes. (Note that the effect of pher-
omone in the S87A T306A double mutant cannot be due to
Far1 activation by phosphorylation at T306, and instead it
may reflect elevated FAR1 transcription [2].) The ability of
Far1-S87A to reduce Cln2-substrate binding even without
pheromone was unanticipated, but it may imply that the un-
modified wild-type (WT) protein is partially active (rather
than inactive) and that this activity becomes more evident in
the S87A mutant due to higher protein levels or presence in
a greater fraction of cells (see below). Overall, the binding re-
sults mirror the G1 arrest phenotypes, implying that interfer-
ence with Cln2-substrate docking relates to the arrest function
of Far1. In further support of this view, we found that Far1
(especially Far1-S87A) also disrupted binding of Cln2 to the
G1/S regulators Sic1 and Whi5 (Figures 2E and S2A), which
are Cdk substrates with Cln1/2 docking sites similar to those
in Ste5 and Ste20 [6, 7].
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Figure 1. Pheromone Signaling Disrupts Cln2-
Substrate Interactions
(A)Mating pheromones signal through amitogen-
activated protein kinase cascade, leading to
phosphorylation and increased expression of
Far1, which is thought to induce G1 arrest by in-
hibiting Cln-Cdk complexes.
(B) Far1 could inhibit cyclin-substrate docking
(left) or Cln-Cdk kinase activity (right).
(C) Cells harboring Cln2-myc (expressed from
the CYC1 promoter; see Figure S1) and a galac-
tose-inducible GST fusion to the Ste20 N termi-
nus (Ste20*) were induced with galactose with
or without pheromone (a factor) for varying times.
Complexes were captured on glutathione Se-
pharose. Bound and input samples were
analyzed by anti-myc and anti-GST blots.
(D) Binding of Cln2-myc to galactose-inducible
GST-Ste20* or GST-Ste5*, induced with or
without pheromone. Note that pheromone
disruption of Cln2-substrate binding was lost in
far1D cells.
See also Figure S1.
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GST-Cln2 fusion was used to coprecipitate full-length sub-
strates (Ste20 and Ste5). Binding of each substrate to GST-
Cln2 required their docking sequences (Figures S2B and
S2C) and was strongest in far1D cells, weakest in FAR1-
S87A cells, and intermediate in FAR1-WT cells (Figures 2F
and S2). This trend was seen even without pheromone treat-
ment, further reinforcing the notion that unmodified Far1 is
partially active. Importantly, Far1 did not affect binding of
Cln2 to its partner Cdk molecule, Cdc28 (Figures 2F and
S2E). The effect of pheromonewas less evident in these exper-
iments than when using the previous (reverse) procedure,
perhaps because chronic Cln2 expression can induce Far1
degradation, counteracting its activation by pheromone. Over-
all, however, the results confirm the disruptive effect of Far1
and argue that it blocks interactions between intact Cln2-
Cdk complexes and their substrates.
Because Far1 binds Cln-Cdk complexes [3, 5, 8], we asked
whether Far1 and substrates bind Cln2 competitively and
whether Far1 outcompetes substrates via higher concentra-
tion or affinity. First, we compared their concentrations by
marking Far1 and substrates with the same epitope tag
(3xV5). Far1 levels ranged between those of Ste20 and Ste5,
depending on whether it had been induced by pheromone or
stabilized by the S87A mutation (Figure 3A). Next, we used
cells that simultaneously expressed V5-tagged forms of Far1
and Ste20 to compare their binding to Cln2 (Figure 3B). The
results suggest that Far1 binds Cln2 more favorably, as total
Far1-WT was much less abundant than Ste20 and yet it bound
Cln2 at equal or greater levels. Similarly, Far1-S87A was
comparably abundant to Ste20 yet showed disproportionally
greater binding to Cln2. When comparing WT and S87A forms
of Far1, the increased Cln2 binding to the S87A mutant was
accompanied by reduced binding to Ste20, implying thatFar1 competeswith Ste20. Indeed, pher-
omone caused increased Cln2-Far1
binding and reduced Cln2-Ste20
binding. Collectively, these results
suggest that Far1 binds Cln2 in a way
that is mutually exclusive with Cln2-substrate docking and that the preferential binding of Far1
allows it to outcompete substrates.
We reasoned that Far1 should be in excess of Cln2 in order
to effectively outcompete Cln2-substrate interactions. There-
fore, we compared their levels as cells approached the critical
point of cell-cycle commitment, or ‘‘Start.’’ Using synchronous
cultures inwhich both Far1 andCln2 had the same epitope tag,
we monitored protein levels and the ability of cells to arrest in
G1 in response to pheromone (Figures 3C and S3). Far1 was
generally in large excess over Cln2 as cells approached Start,
and a sharp increase in Cln2 corresponded to the first appear-
ance of committed cells. It did not seem that Cln2 must reach
peak levels or exceed Far1 for cells to pass Start but rather it
only must begin to accumulate. This pattern fits previous
findings that Start occurs simultaneous with CLN2 promoter
firing [12] and is reminiscent of the mammalian cell restriction
point occurring at very low levels of cyclin E [13, 14]. Thus, it
may be necessary for Far1 to substantially exceed cyclin levels
to prevent Start, whereas cyclin levels may not need to exceed
Far1 to pass Start, perhaps because the positive feedback
loop governing Cln1/2 expression [15] makes them destined
to overwhelm Far1 once their expression begins. In accord
with recent work [12], the Far1-S87A mutant caused mild
delays in commitment and Cln2 expression, though to varying
degrees (Figures 3C and S3). Notably, the Far1-S87A protein
was not strongly overexpressed compared to peak levels
of Far1-WT, but it was present over a broader range of the
cell cycle (Figures 3C and S3). Hence, the increased inhibitory
activity of Far1-S87A seen in preceding experiments (using
asynchronous cultures) may primarily reflect an increase
in the fraction of cells expressing Far1 rather than in its
concentration.
Cdk phosphorylation of both Ste20 and Ste5 alters
their electrophoretic mobility [6, 16–18]. By using extended
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Figure 2. Far1 Inhibition of Docking Correlates with G1 Arrest Ability
(A) Pheromone triggers phosphorylation of Far1 at T306, which promotes G1 arrest, whereas Cdk phosphorylates Far1 at S87, which promotes its degra-
dation [5].
(B) The indicated FAR1 strains were tested for pheromone arrest. Cell lawnswere overlaidwith disks containing 20 ml of a factor (20 or 100 mM) and incubated
at 30C for 2 days.
(C and D) Binding of Cln2-myc to GST-Ste20* or GST-Ste5* was analyzed (as in Figure 1) using strains with different FAR1 alleles, in the presence or absence
of pheromone.
(E) Far1 disrupts Cln2 binding to Sic1 andWhi5. Sic1DC (residues 1–214) lacks its Cdk-inhibitor domain but includes its Cln1/2 docking site [6, 7]. Pheromone
was omitted from these assays because it affected GST-Whi5 levels.
(F) Far1 disrupts binding of GST-Cln2 to full-length Ste20. Strains harbored a PGAL1-GST-CLN2 plasmid or GST vector, plus V5-tagged Ste20. To reduce
effects of pheromone on Cln2 levels, we used a truncated Cln2 (residues 1–372), which lacks its destabilizing C terminus [11]. Cells were inducedwith galac-
tose 6pheromone; bound complexes were captured and analyzed by anti-V5, anti-GST, and anti-Cdc28 blots. Graphs quantify relative levels of Ste20
binding (mean 6 SEM; n = 3).
See also Figure S2.
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1392electrophoresis to better resolve Ste20 forms, we found that
pheromone and Far1 inhibited Cln2-driven phosphorylation
(Figures 4A and S4A). Specifically, Cln2 expression in far1D
cells converted Ste20 to its slowest-mobility, phosphorylated
form. Pheromone had no effect in far1D cells, but it reduced
Ste20 phosphorylation in FAR1-WT cells. In FAR1-S87A cells,
Ste20 phosphorylation was reduced even without pheromonetreatment, and pheromone caused a further reduction. The
T306A mutant was ineffectual, while the S87A T306A double
mutant showed a result intermediate between the two single
mutants. Collectively, these results suggest parallel effects
of Far1 on substrate docking and substrate phosphorylation
by Cln2-Cdk. Chemical inhibition of Cdk activity was not suffi-
cient to reduce Cln2-Ste20 binding, and Far1-S87A was
AB
C
Figure 3. Far1 Outcompetes Substrates for Binding to Cln2
(A) Far1, Ste5, and Ste20were taggedwith the identical 3xV5 tag to compare
protein levels. Far1 (WT or S87A) was expressed from its native genomic
locus; Ste5 and Ste20 were expressed from their native promoters on
low-copy-number plasmids. Whole-cell extracts were prepared and equiv-
alent amounts of total protein were analyzed by SDS-PAGE and anti-V5
blots.
(B) Strains with V5-tagged Far1 or Far1-S87A harbored a V5-Ste20 plasmid
plus galactose-inducible GST-Cln2 or GST vector. Cells were induced with
galactose with or without pheromone, and then binding of Far1 and Ste20 to
GST-Cln2 was assayed.
(C) Strains with V5-tagged Far1 and Cln2 were synchronized by arrest in
mitosis (using a cdc15-2 mutant). At various times after release, aliquots
were taken to assess protein levels and then treated with pheromone to
assesswhether they could still arrest in G1 or had passed Start (committed).
Signal levels in the two blots are directly comparable, as all steps were per-
formed in parallel using equal protein loading. Graphs show mean 6 SEM
(n = 4–6).
See also Figure S3 for additional tests.
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1393equally disruptive with and without Cdk inhibition (Figure 4B),
suggesting that reduced binding causes reduced phosphory-
lation rather than vice versa. Notably, to our knowledge, these
results provide the first demonstration that pheromone and
Far1 reduce phosphorylation of Cdk substrates in vivo (see
the Discussion). In contrast, we saw no reduction in phosphor-
ylation of the Cln1/2 C-termini (Figure S4B) or Far1 itself (Fig-
ure 3B, top), indicating that Far1 does not inhibit all Cln-Cdk
phosphorylation events equally.
Finally, we asked whether the ability of Far1 to disrupt sub-
strate phosphorylation is due to inhibition of Cln2-substrate
docking or Cln2-Cdk kinase activity or a combination of
both. To address this point, we compared Cdk substrates
with and without Cln2 docking motifs. Using an approach to
be elaborated elsewhere (S.B. and P.M.P., unpublished
data), we replaced a native docking interaction with a foreign
leucine zipper (Figure S4Eii), thereby allowing phosphorylation
of a single substrate to be driven by either a native cyclin dock-
ing site or an artificial linkage. Then, we analyzed phosphory-
lation driven by different cyclins and the effects of Far1.
When the substrate harbored a native ‘‘LP’’-type Cln2 docking
site, its phosphorylation was inhibited strongly by Far1-S87A,
but when the leucine zipper was used, the degree of inhibition
was substantially reduced, though not eliminated (Figures 4C
and 4D). These results imply that Far1 inhibits substrate dock-
ing strongly, with a residual effect on some nondocking func-
tion such as Cdk kinase activity. This residual effect might
also signify a reduction in kinase processivity mediated by
theCks1 subunit of theCdk complex [19–21], though it was still
evident when the role of Cks1 was blocked (by changing thre-
onine phosphorylation sites to serine; Figure S4D). It is also
notable that this residual effect was only seen with the G1/S
cyclins Cln1 and Cln2 (Figure 4D), even though Far1-S87A
could bind all cyclins (Figure 4E). Interestingly, however,
when the substrate contained an ‘‘RXL’’ docking motif favored
by S-phase cyclins such as Clb5 [6, 22, 23], Far1-S87A could
mildly inhibit Clb5-driven phosphorylation (Figure 4D), again
suggesting that docking-dependent phosphorylation is more
susceptible to inhibition by Far1. To help quantify the extent
of phosphorylation, we performed related experiments using
a variant substrate with only two electrophoretic mobility
forms: unphosphorylated and phosphorylated (Figure 4F).
Here, pheromone treatment of Far1-S87A cells almost
completely reversed phosphorylation driven by the native
Cln2 docking site (Figure 4F, top) but had only a mild effect
when the leucine zipper was used (Figure 4F, bottom). Collec-
tively, these results suggest that Far1 can reduce Cdk
phosphorylation of substrates irrespective of docking, but
substrates that require docking are especially sensitive to
Far1. Therefore, Far1 may engage cyclin-Cdk complexes in a
way that simultaneously disrupts both substrate recognition
and kinase activity.
Discussion
This study addresses long-standing uncertainties about how
yeast pheromone signaling and the presumed CKI protein
Far1 promote cell-cycle arrest. Our findings reveal an unsus-
pectedmode of Cdk regulation, in which an extracellular signal
stimulates an inhibitory factor, Far1, to disrupt interactions of
specific cyclin-Cdk complexes with substrates. Far1 appears
to disrupt Cln2-substrate docking by binding Cln2 more favor-
ably so that it outcompetes substrates, and mutant analyses
suggest that this effect parallels its ability tomediate G1 arrest.
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Figure 4. Effects of Far1 and Pheromone on Cdk Phosphorylation In Vivo Using Substrates with Native and Artificial Docking Interactions
(A) Extracts of cells harboring V5-Ste20 and galactose-inducible GST-Cln2, as in Figure 2F, were analyzed by extended electrophoresis to resolve the extent
of Ste20 phosphorylation triggered by Cln2 expression. See Figure S4A for replicates.
(B) Cdk inhibition alone does not disrupt Cln2-Ste20 binding. Strains with a drug-sensitive Cdk (cdc28-as2) harbored V5-taggedSte20 plus galactose-induc-
ible GST-Cln2 or GST vector. Cells were induced with galactose either with or without the ATP analog 1-NM-PP1 (15 mM), and GST fusions were captured.
Total and bound Ste20 were analyzed by anti-V5 blots.
(C) The indicated FAR1 strains harbored a plasmid expressing GST-Cln2 with an attached leucine half-zipper (lz), plus a plasmid expressing an hemagglu-
tinin (HA)-tagged Cdk substrate with either the matching half-zipper or an LP-type Cln1/2 docking site (see Figure S4Eii). Cultures were preincubated for
2 hr 6a factor (0.1 mM) and then induced with galactose for 2 hr. Substrate phosphorylation [6] and GST-Cln2 expression was monitored by anti-HA and
anti-GST blots, respectively. Figure S4C shows that leucine zipper binding is resistant to pheromone and Far1.
(D) FAR1-S87A and far1D strains coexpressing GST-(lz)-cyclins with an HA-tagged substrate (Figure S4Eii) were induced with galactose for 2.5 hr. Levels of
GST-(lz)-cyclins were monitored in each experiment; one representative anti-GST blot is shown. Note that, aside from effects of Far1, these results confirm
that cyclin docking drives substrate use, because switching the docking site alters which cyclins are effective, as seen previously [6].
(E) GST-(lz)-cyclin plasmids were introduced into a strain with V5-tagged Far1-S87A. Cultures were inducedwith galactose for 1.5 hr and then association of
Far1 with the GST-tagged cyclin was assayed.
(F) Strains coexpressed GST-(lz)-Cln2 with HA-tagged substrates that each show only twomobility forms (see Figure S4Eiii), which makes it easier to quan-
tify phosphorylation. Cultures were preincubated with a factor (0.1 mM, 30 min) and then induced with galactose (40 min). Graphs (mean 6 SEM, n = 3–4)
show the signal in the upper band as a percentage of the total signal (% phos.).
See also Figure S4.
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1395Because Cln1/2 docking enhances substrate phosphorylation
[6, 7], inhibition of docking by Far1 should contribute to
reduced substrate phosphorylation in vivo, in addition to any
effects of Far1 on Cdk activity per se. Indeed, our findings
suggest that Far1 is a multimode inhibitor that separately
disrupts both Cdk activity and substrate docking. This com-
bined effect raises the possibility that Far1 has the strongest
inhibitory effect on substrates that are most dependent on
docking, which might include proteins with inherently poor
(e.g., nonconsensus) phosphorylation sites or those that
must be phosphorylated at multiple positions. Similar themes
could also apply to other kinases.
We find that the ability of Cln1/2-Cdk to phosphorylate sub-
strates in vivo can be inhibited by pheromone and Far1.
Remarkably, to our knowledge, this is the first such demon-
stration. Although there are numerous prior examples in which
Cdk substrates are unphosphorylated in pheromone-arrested
cells, this can be explained by the fact that cyclins are not
expressed in G1 phase, and hence it does not necessarily
indicate that the kinase activity of cyclin-Cdk complexes is
reduced. Here, by expressing cyclins independent of cell-
cycle position, we could detect regulation of phosphorylation
by a set amount of Cln1/2-Cdk in vivo. Also, by linking different
cyclins to substrates using a common leucine zipper, we could
compare their sensitivity to Far1. Of note, compared to Cln1/2-
Cdk, Cln3-Cdk seemed less susceptible to Far1 inhibition,
which could underlie different roles for these cyclins in driving
cell-cycle re-entry after pheromone arrest [24].
Surprisingly, Far1 couldpartially interferewithCln2-substrate
binding and phosphorylation even without pheromone treat-
ment. Prior findings implied that Far1 must be activated,
because G1 arrest required pheromone-induced phosphory-
lation of Far1 at T306 [5] and FAR1 overexpression was not
sufficient [25]. We suggest a new interpretation in which un-
phosphorylated Far1 is partially active but is less potent than
when phosphorylated at T306. This view is supported by our
binding andphosphorylationdata aswell asby thepartial arrest
observed in FAR1-S87A T306A cells, which shows that T306
phosphorylation is not absolutely essential. It is also relevant
to findings that far1D cells show accelerated entry into the cell
cycle [26] and that FAR1-S87A cells show a delay in Start [12].
Because Far1 is expressed only during a narrow pre-Start win-
dow of the cell cycle [27], the partially active state would nor-
mally be restricted to cells poised for G1 arrest, but detection
of this state was enhanced when using the stabilized S87A
mutant, which is expressed in a larger fraction of cells. This
mutant also revealed that inhibitory effects of Far1 are at least
partly independent of T306 phosphorylation. Yet, T306 phos-
phorylation makes Far1 a more potent inhibitor, likely via
enhanced binding to Cdk complexes [5] and possibly via
engaging thephosphothreoninebindingpocket inCks1 [20,21].
The specific mechanism by which Far1 disrupts Cln2 dock-
ing is not yet known. Currently, there are no structural data on
the Cln2-substrate binding interface, but the short docking
motifs [6, 7] likely bind a peptide-recognition pocket on the
cyclin, as with RXL motif recognition by S phase cyclins [28].
Thus, Far1 could displace substrates either by having a
higher-affinity docking peptide or by interacting with a broader
region of Cln2 in a way that obscures peptide recognition. The
latter view may be favored by the fact that two separate parts
of Far1 are required to bind Cln2 [3]. This view is also reminis-
cent of mammalian CKI proteins p21 and p27, whose RXL
sequences contribute to cyclin binding and Cdk inhibition
[29–31], but as only a small part of a much larger bindinginterface involving both the cyclin and Cdk subunits [32]. In
fact, such multipartite interactions may have contributed to
confusion about inhibitory mechanisms for both Far1 and
p21/p27. Namely, complexes of p21 with cyclin-Cdk some-
times retained kinase activity [33, 34], leading to speculation
that under such conditions, the CKI might contact only the
cyclin and not the Cdk [35], a notion later supported by p21
mutants that bind only the cyclin [30]. Analogous heterogene-
ity of Far1-Cln-Cdc28 complexes might explain why kinase in-
hibition was observed in some studies [4], but not others [5]. In
addition, the use of generic substrates that do not require
docking (e.g., histone H1) would have bypassed the ability of
Far1 to regulate this step in either study.
We suggest that Far1 engages the cyclin-Cdk complex in a
way that disrupts multiple distinct functions, including
both substrate docking and kinase activity but perhaps also
others such as Cks1-mediated processivity [19–21]. Multiple
concerted effects may help ensure maximal inhibition. Thus,
in future studies using in vitro assays, it will be important to
compare substrates with a range of requirements, in order to
dissect the effect of Far1 on total kinase activity, utilization
of docking sites, kinase processivity, and multisite phosphor-
ylation. Investigation of these issues will further illuminate how
differential regulation of distinct mechanistic steps in sub-
strate phosphorylation can provide additional layers of control
that fine-tune protein kinase networks.
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